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Breast cancer is now considered to be a systemic disease from the outset, with no correlation seen
between the intensity of local treatment and survival or recurrence. Adjuvant therapy has clearly
demonstrated a reduction in local and distant relapse; neoadjuvant therapy is similarly being assessed. It
aims to treat occult metastases and decrease tumour bulk. Its use has demonstrated down-staging of the
tumour with increased rates of breast-conserving surgery. Though neoadjuvant therapy seems to be
associated with an increase in loco-regional recurrence compared to adjuvant therapy, no overall
difference in survival has been demonstrated. This paper reviews several trials that compare neoadjuvant
to adjuvant therapy, and the controversies around managing the axilla in the neoadjuvant setting.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Themanagement of breast cancer has gone through a signiﬁcant
change in the last few decades, with the super radical mastectomy
no longer a common entity. Breast cancer is now considered to be
a systemic disease from the outset, with most patients with early
breast cancer developing metastases whatever the treatment
undertaken.1 Moreover, the intensity of local treatment does not
correlate with survival and the risk of metastatic recurrence. A
possible explanation to this may be the blood-borne micro-
metastases that are present at initial diagnosis. These observations
have lead to a more conservative approach to surgical intervention
in breast cancer and the concurrent use of medical therapy. A clear
survival beneﬁt has already been shown with adjuvant therapy,
presumably by eradicating occult metastases.2 Neoadjuvant
therapy is now being evaluated in this setting and has shown
encouraging results.
The main aims of neoadjuvant therapy are to treat occult
metastases, decrease the bulk of the tumour and allow breast-
conserving surgery. It seems to have the potential of improving the
results in more advanced cancers, for instance, in cancers with local
ﬁxity. Neoadjuvant therapy trials also offer a means for evaluating
the effectiveness of the systemic agents compared to the adjuvant
setting. The biological rationale for neoadjuvant therapy in breast
cancer has been provided by Fisher and his colleagues. In a mice
cancer model, they demonstrated that tumour excision wasþ44 1912228988.
d).
ciates Ltd. Published by Elsevier Ltassociated with an increase in metastases, and that preoperative
chemotherapy prevented these changes.3
Several treatment modalities have been assessed as neo-
adjuvant therapy. Most trials have been on neoadjuvant chemo-
therapy, although more recently, neoadjuvant endocrine therapy
and neoadjuvant trastuzumab have also been assessed.2. Randomized trials of neoadjuvant chemotherapy
More than nine trials have compared neoadjuvant chemo-
therapy against adjuvant treatment using the same combination of
chemotherapy. Several outcomes have been measured, which are
listed in Table 1.
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-18 trial is the largest of these trials which has included
1523 patients with T1-3N0-1M0 breast cancers.4–6 Patients were
randomized to receive four cycles of cyclophosphamide and
doxorubicin either pre- or post-surgery. In the neoadjuvant group,
the clinical response rate (CRR) was 80%, with 30% showing
a complete clinical response (cCR). The complete pathological
response (cPR) was 13%. Though the breast conservation therapy
(BCT) rate was higher among the neoadjuvant group (67%
compared to 60% in the adjuvant group), the local recurrence rate
was also higher (15% vs. 7%). In terms of survival, there was no
signiﬁcant difference in disease-free or overall survival between
the two groups at a nine-year follow-up. The survival was, however,
signiﬁcantly higher in those that showed a complete pathological
response (overall and disease-free survival rates of 85% and 75%,
respectively). The European Organization for Research andd. All rights reserved.
Table 1
Outcome measures in clinical trials.
cRR Clinical response rate
cCR Complete clinical response
pCR Complete pathological response, the absence of residual or in situ
disease following therapy
OS Overall survival
BCT Breast-conserving therapy
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recruited 698 patients with T1c-4b breast cancers.7 These were
randomized to a neoadjuvant and an adjuvant arm receiving four
cycles of 5-ﬂuorouracil, epirubicin and cyclophosphamide either
pre- or post-operatively. The cRR, cCR rate, and pCR rate were 49%,
7%, and 4%, respectively. An improved survival was seen in patients
receiving neoadjuvant chemotherapy with complete pathological
response.
In the European Cooperative Trial in Operable breast cancer
(ECTO), Gianni et al. randomized 1355 patients into a neoadjuvant
and two adjuvant arms with a combination of chemotherapeutic
agents.8 Twenty-three percent of the patients in the neoadjuvant
arm had a complete pathological response; the BCT rate was also
better in the neoadjuvant arm (65% vs. 34%; p< 0.001). The disease-
free and overall survival in all the arms was similar at 5 years of
follow-up. Several other randomized trials comparing neoadjuvant
and adjuvant chemotherapy have shown an advantage in terms of
an increase in BCT, though no survival beneﬁt has been shown
(Table 2). In fact, it appears that neoadjuvant chemotherapy may
increase the rate of loco-regional recurrence.
3. Hormonal inﬂuence on neoadjuvant chemotherapy
The response of breast tumours to neoadjuvant therapy appears
to vary with the hormone expression proﬁle of the tumour, with
estrogen receptor (ER) positive tumours having a worse response.
In the M.D. Anderson Cancer Centre (MDACC) trial, Buzdar et al.
showed that ER-negative tumours have signiﬁcantly higher pCR
rates (21%) compared to ER-positive tumours (5%).9 In the ETCO
trial,8 ER-negative tumours had a pCR of 42% compared to ER-
positive tumours which was 12%. Similarly, in the NSABP B-27 trial,
the pCR rates were 23% and 6% for ER-negative and ER-positive
tumours, respectively.10
4. Neoadjuvant endocrine therapy
Neoadjuvant chemotherapy is associated with signiﬁcant
toxicity, especially in elderly patients. In this setting, neoadjuvant
endocrine therapy has been emerging as an alternate option in
hormone receptor positive breast cancer in post-menopausal
women.Table 2
Randomized clinical trials of neoadjuvant chemotherapy.
Trial Median follow-up
(months)
cRR% pCR
NSABP B-18, Fisher et al., Woolmark et al.4–6 108 80 13
EORTC, Van der Hage et al.7 56 49 4
ECTO, Gianni et al.8 31 78 23
Mauriac9 124 81 –
Scholl10 66 85 –
Makris11 48 83 10
Powles12 – 10
Semiglazov et al13 53 69 29
Gazet et al.14,15 60 – –Tamoxifen has been used as primary treatment in patients with
inoperable and locally advanced breast cancer in elderly patients
for several years with response rates in excess of 30%.11 In studies
where tamoxifenwas given in one groupwith surgical intervention
in the other, a signiﬁcant increase was noted in the local progres-
sion of the disease in the tamoxifen group.12,13 Comparing tamox-
ifen only with surgery and tamoxifen, Mustacchi et al.
demonstrated an even greater proportional increase in local
recurrence in the tamoxifen only group.14 It must be borne in mind,
however, that these studies were not designed to assess tamoxifen
in the neoadjuvant setting and merely show its effects as a primary
treatment.
Focus has recently been placed on the aromatase inhibitors,
several of which are now being used in the adjuvant setting.
Letrozole, a highly selective aromatase inhibitor, was initially
shown to beneﬁt postmenopausal ER-positive patients in a non-
randomized study in Edinburgh.15 Thereafter, the PO24 trial was
published that compared 4 months of letrozole and 12 months of
tamoxifen in 337 postmenopausal patients with ER and/or PR-
positive tumours.16 At the time of diagnosis, all patients were
considered ineligible for breast conservation. The letrozole group
demonstrated a 55% objective clinical tumour response (deter-
mined by breast palpation) compared with a 36% in the tamoxifen
group (p< 0.001). Objective response with ultrasound demon-
strated a similar superior efﬁcacy of letrozole compared to
tamoxifen. There were more patients in the letrozole group who
were found eligible for breast-conserving surgery after treatment
(45%) compared to those in the tamoxifen group (35%, p¼ 0.022).
Two randomized trials have been published comparing the
efﬁcacy of anastrozole and tamoxifen in postmenopausal women
with hormone receptor positive tumours in the neoadjuvant
setting. The IMPACT study (IMmediate Preoperative Arimidex,
Tamoxifen or Combined with Tamoxifen) was a large multi-centre
trial that recruited 330 patients from Germany and the UK.17
Patients were randomized to either anastrozole, tamoxifen or both
for 3 months pre-operatively. No signiﬁcant difference in objective
response (measured by callipers and ultrasound) was noted
between the groups. However, the number of patients that were
considered suitable for BCT at 3 months was signiﬁcantly higher in
the anastrozole group (46% vs. 22%; p¼ 0.03). Interestingly,
patients with her-2 positive tumours demonstrated a higher clin-
ical response rate in the anastrozole group (p¼ 0.18). The PROACT
(PReOperative Arimidex Compared with Tamoxifen) trial was
another large, multi-centre trial performed in several centres in
Europe and USA.18 This trial recruited 451 postmenopausal women
with large operable ER- or PR-positive tumours. Patients were
randomized to receive either anastrozole or tamoxifen alongside
chemotherapy. Surgery was undertaken at 3 months and the same
treatment regime continued for a further 5 years. No signiﬁcant
difference in objective response rate, assessed by ultrasound and
calliper measurement, was seen between the groups. However, in% BCT% (compared
to adjuvant)
Overall survival (%)
(compared to adjuvant)
Local recurrence (%)
(compared to adjuvant)
67 vs. 60 69 vs. 70 11 vs. 8
37 vs. 21 82 vs. 84 10 vs. 9
65 vs. 34 – –
NA 55 vs. 55 8 v 5
82 vs. 77 86 vs. 78 24 v 18
89 vs. 78 80 vs. 80 3 vs. 4
– –
– 86 vs. 78 –
65 vs. 87 79 vs. 87 –
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trend in favour of anastrozole. In the same group (n¼ 314), 43% of
patients initially considered ineligible for BCT were considered
eligible in the anastrozole arm compared to 30.8% in the tamoxifen
arm (p¼ 0.04).
Exemestane has similarly been shown to have a promising role
in the neoadjuvant treatment of breast cancer. Most studies of
exemestane are small, non-randomized studies with low number
of patients. In one of these studies by Miller et al., exemestane was
administered to 12 women with large operable or locally advanced
primary breast cancer.19 Of the 12 patients treated, 10 had a greater
than 50% reduction in tumour size. Conversion rate to breast
conservation surgery was high with only 2 of the 10 patients
initially considered to require mastectomy actually requiring one
(80% breast conservation rate). In another study, Tubiana et al.
examined 42 postmenopausal women with ER-positive operable
breast cancer by giving them exemestane for 16 weeks pre-oper-
atively.20 Seventy-three percent of the patients showed a clinical
objective response, as measured by ultrasound, whereas 57% of the
patients were able to have BCT. In the GENARI trial, 27 post-
menopausal womenwith hormone receptor positive tumours were
similarly treated with 16 weeks of exemestane pre-operatively.21
Ten patients had a partial clinical response, whereas breast-
conserving surgery could be offered to 14 patients. A comparatively
larger study on exemestane in the neoadjuvant setting has been
reported in which 151 women with hormone receptor positive
breast cancer were randomized to either exemestane or tamoxifen
for 3 months prior to surgery.22 Clinical objective response as
measured by palpationwas higher in the exemestane group (76.3%)
compared with tamoxifen (40.0%; p¼ 0.05), though there were no
signiﬁcant difference in the response rate when measured by
ultrasound and mammogram. However, a higher rate of BCT was
seen in the exemestane group compared to tamoxifen (36.8% vs.
20.0%; p¼ 0.05).
5. Trastuzumab as neoadjuvant therapy
HER-2, the human epidermal factor receptor, is over-expressed
in 15%–25% of breast cancers.23 Several studies have shown
a survival beneﬁt of trastuzumab, a HER-2 receptor antibody, in
metastatic breast cancer in combination with chemotherapy. There
are several small trials that have shown a beneﬁt of using trastu-
zumab in the neoadjuvant setting. One of the trials with trastuzu-
mab had to be closed early due to its signiﬁcant superiority in the
group in which this was used. In this randomized study by Buzdar
et al.,24 patients were being randomized to a preoperative
chemotherapy only group (four cycles) and to a group with the
same chemotherapy regime along with weekly trastuzumab for 24
weeks. With only 42 of the planned 164 patients recruited, the
study showed a marked superiority in the trastuzumab plus
chemotherapy arm with a pCR of 65% compared to a pCR of 26% in
the other arm (p¼ 0.016). Several other smaller studies of trastu-
zumab-containing neoadjuvant chemotherapy have described pCR
rates ranging from 7 to 78% (reviewed in25). Cardiac toxicity
remains one of the main drawbacks of its use. Its optimal duration
of administration and its impact on long term outcome await
further details, with several trials in progress.
6. Neoadjuvant therapy and breast-conserving surgery
Most trials using neoadjuvant chemotherapy have shown an
increase in BCT. In the NSABP B-18 trial, 67% of the patients in the
neoadjuvant group underwent BCT compared to 60% in the adju-
vant group.4–6 Table 2 illustrates the rates of BCT in various trials. It
thus appears that neoadjuvant therapies may offer the opportunityto down-stage the tumours and enable more women to undergo
breast-conserving surgery.
7. Does neoadjuvant therapy alter loco-regional recurrence
and survival?
Mauri et al. have published a meta-analysis of nine randomized
trials of neoadjuvant vs. adjuvant therapy in patients with breast
cancer.26 The analysis included 4000 patients with 966 instances of
death, 1310 disease progression, 520 loco-regional recurrences and
745 distant recurrences. The authors found no difference in death
and distant recurrences between the different arms. There was
a 22% increase in relative risk for loco-regional recurrence associ-
ated with neoadjuvant treatment (p¼ 0.015). However, this
difference was less than 5% in seven trials and 16.1% in one trial. An
interesting point highlighted in the meta-analysis was that the
increased risk of loco-regional recurrence was mainly driven by
three trials in which no surgical intervention had been adopted. In
these trials, patients received radiotherapy only after the neo-
adjuvant chemotherapy. Though the other six trials did not show as
signiﬁcant a difference in loco-regional recurrence compared to the
three trials mentioned, it still showed an increase, and interpreta-
tion of the review must be done with caution.
8. Management of the axilla in neoadjuvant therapy
Axillary lymph node status is regarded as a prognostic indicator
in invasive breast cancer. Sentinel lymph node biopsy (SLNB) is
being used increasingly in patients with early breast cancer in
predicting node status. The remainder of the axilla can be consid-
ered to be tumour free when the sentinel lymph node is negative.27
SLNB has an identiﬁcation rate of 86–93% and a false negative rate
of 7–13% (reviewed in.23 SLNB assessment becomes difﬁcult in the
neoadjuvant setting due to the histological changes which may
alter the accuracy of SLNB and lead to an increase in false negative
results. Several small studies have examined the efﬁcacy of SLNB in
this setting. One of the largest of these, the NSABP B-27, involved
428 patients from several centres that underwent SLNB and axillary
lymph node dissection following neoadjuvant therapy.28 The
sentinel lymph nodes were successfully identiﬁed and removed in
85% of the patients. The false negative ratewas 11%, not far from the
false negative rate of SLNB in the normal clinical setting. Charfare
et al. have combined the results of 14 studies and describe an
overall detection rate of SLNB in 89% of the patients with a false
negative rate of 11%.29 These ﬁgures are almost comparable to those
obtained prior to neoadjuvant therapy and suggest that sentinel
lymph node biopsy may be applicable in the neoadjuvant setting.
The timing of SLNB in the neoadjuvant setting is also contro-
versial, with advocates for both pre- and post-neoadjuvant SLNB.30
Performing the SLNB in the pre-neoadjuvant scenario may provide
a more deﬁnite node status at presentation and provide the ther-
apists with an opportunity to tailor the treatment based on the
node status. However, it exposes the patients to a further surgical
procedure. The number of positive lymph nodes may be altered by
the neoadjuvant therapy and may alter further treatment plans in
the axilla. In the NSABP B-18 trial,4–6 axillary down-staging has
been described following neoadjuvant chemotherapy (41% node
positive in the neoadjuvant group compared to 57% in the adjuvant
group). In patients where there has been a signiﬁcant reduction in
lymph node disease, a pre-neoadjuvant SLNB may subject them to
an unnecessary axillary lymph node dissection later on. The other
alternative may be to perform the SLNB after neoadjuvant therapy.
This has also been met with several controversies. Though this may
mean a reduction in the surgical procedure for the patient as this
can be combined with the surgical procedure on the breast, the
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before neoadjuvant therapy.30 Moreover, performing the SLNB after
adjuvant therapy may be technically more demanding and involve
a signiﬁcant learning curve.9. Role of radiotherapy after neoadjuvant therapy
In patients treated with neoadjuvant chemotherapy and
mastectomy, post-mastectomy radiation has been shown to lower
the rate of loco-regional recurrence. Huang et al. performed
a retrospective analysis of 542 patients who were treated in six
prospective trials within the same institution and compared the
data with 134 patients with similar treatment but without radia-
tion.31 They demonstrated a reduced loco-regional recurrence rate
in irradiated patients (10-year recurrence rate 11% vs. 22%.
p¼ 0.0001). The beneﬁt was more in patients with clinical T3 & T4
stage, a tumour size of >5.1 cm and in those with more than four
positive nodes. This led to their recommendation that patients with
locally advanced disease at presentation or with four or more
positive lymph nodes should be considered for radiation after
neoadjuvant chemotherapy and mastectomy. Based on their
review, it remains unclear whether patients with stage II breast
cancer with less than three positive lymph nodes would beneﬁt
from radiation therapy in a similar setting.10. Summary
Neoadjuvant therapy offers several beneﬁts. It gives an oppor-
tunity to assess the tumour response to the agent in vivo by tumour
size assessment at regular intervals. It also provides a unique
opportunity to study the biology of the tumour. Several modalities
of neoadjuvant therapy have been examined and have all shown
variable success. Neoadjuvant chemotherapy has demonstrated
a down-staging of the tumours which provides an opportunity for
more breast-conserving surgery. Though no difference in survival
has been demonstrated in trials comparing neoadjuvant with
adjuvant chemotherapy, neoadjuvant chemotherapy seems to be
associated with an increase in loco-regional recurrence. Neo-
adjuvant hormone therapy and trastuzumab have also shown
promising results. The role of sentinel lymph node biopsy and
radiotherapy in this setting is evolving. There are several ongoing
trials and the publication of these may yield more conclusive
therapeutic choices.
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